A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of ...
An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Dos ...
A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms o ...
An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4 An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From ...
Advanced Idiopathic Parkinson's Disease
Drug: Rotigotine
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.
Completed
30 Years
80 Years
All
87
Phase 4
United States;Korea, Republic of;Malaysia;Singapore;Taiwan
Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's D ...
Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Oral Non-Ergot Dopamine Agonists Influence of the Non-Ergot Dopamine Agonist Piribedil on Vigilance and Cognitive Function in Patient ...